secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beyond Air, Inc. (XAIR)
CIK:        0001641631
Form:       8-K
Filed at:   2023-02-13T23:59:59+00:00
Accession:  0001493152-23-004522
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beyond Air Q3 FY2023 net loss $12.7M; expects first LungFit PH sales in March quarter
--------------------------------------------------------------------------------

- Net loss attributable to shareholders $12.7M ($0.43/share) vs $7.7M ($0.29) a year ago.
- Cash and equivalents $63.2M; quarterly cash burn $9.3M in line with $8.0-10.0M guidance.
- R&D expenses $5.0M (+99% YoY) from Beyond Cancer scale-up; G&A $8.9M (+82% YoY) for commercial launch.
- CE Mark for LungFit PH expected H1 FY2024; PMA supplement for cardiac label in H1 CY2023.
- US VCAP trial planned Q4 CY2023; NTM trial in H2 FY2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641631/000149315223004522/0001493152-23-004522-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641631/000149315223004522/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-004522

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer